SCHEMBL6945691

SCHEMBL6945691

N#Cc1c(N2CCc3ccccc3CC2)nc(CCO)[nH]c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 1/20 0.45
ALDH1A1 P00352 9/20 0.38
KDM4E B2RXH2 8/20 0.38
HSD17B10 Q99714 4/20 0.38
HPGD P15428 4/20 0.38
GAA P10253 3/20 0.37
ALOX15 P16050 2/20 0.37
ATM Q13315 1/20 0.37
PKM P14618 1/20 0.37
MAPT P10636 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
HTT P42858 2/20 0.37
HIF1A Q16665 2/20 0.37
POLB P06746 1/20 0.37
TP53 P04637 1/20 0.37
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 3/20 0.36
USP2 O75604 1/20 0.36
CASP1 P29466 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6952723 0.91 PDE9A (0.44) PDE9AALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6945649 0.89 PDE9A (0.41) PDE9AALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6951302 0.87 PDE9A (0.40) PDE9AALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6951286 0.84 PDE9A (0.40) PDE9AALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6952968 0.84 HTR1A (0.41) PDE9AALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6949420 0.81 DAO (0.40) PDE9AALDH1A1KDM4EHSD17B10HPGD
SCHEMBL6948400 0.80 XDH (0.51) ALDH1A1KDM4EHSD17B10HPGDATM
SCHEMBL6949962 0.80 GAA (0.43) ALDH1A1KDM4EHSD17B10HPGDGAA
SCHEMBL6951832 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EHSD17B10HPGDGAA
SCHEMBL6955411 0.79 RXFP1 (0.54) ALDH1A1KDM4EHSD17B10HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP claimed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US claimed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP claimed
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed